Literature DB >> 16319409

Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder.

Dan Chisholm1, Mark van Ommeren, Jose-Luis Ayuso-Mateos, Shekhar Saxena.   

Abstract

BACKGROUND: Bipolar disorder has been ranked seventh among the worldwide causes of non-fatal disease burden. AIMS: To estimate the cost-effectiveness of interventions for reducing the global burden of bipolar disorder.
METHOD: Hospital- and community-based delivery of two generic mood stabilisers (lithium and valproic acid), alone and in combination with psychosocial treatment, were modelled for 14 global sub-regions. A population model was employed to estimate the impact of different strategies, relative to no intervention. Total costs (in international dollars (I$)) and effectiveness (disability-adjusted life years (DALYs) averted) were combined to form cost-effectiveness ratios.
RESULTS: Baseline results showed lithium to be no more costly yet more effective than valproic acid, assuming an anti-suicidal effect for lithium but not for valproic acid. Community-based treatment with lithium and psychosocial care was most cost-effective (cost per DALY averted: I$2165-6475 in developing sub-regions; I$5487-21123 in developed sub-regions).
CONCLUSIONS: Community-based interventions for bipolar disorder were estimated to be more efficient than hospital-based services, each DALY averted costing between one and three times average gross national income.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16319409     DOI: 10.1192/bjp.187.6.559

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  19 in total

1.  Choosing cost-effective interventions in psychiatry: results from the CHOICE programme of the World Health Organization.

Authors:  Dan Chisholm
Journal:  World Psychiatry       Date:  2005-02       Impact factor: 49.548

Review 2.  Cost effectiveness in low- and middle-income countries: a review of the debates surrounding decision rules.

Authors:  Samuel D Shillcutt; Damian G Walker; Catherine A Goodman; Anne J Mills
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

Review 3.  A Systematic Review and Critical Appraisal of Economic Evaluations of Pharmacological Interventions for People with Bipolar Disorder.

Authors:  Ifigeneia Mavranezouli; Joran Lokkerbol
Journal:  Pharmacoeconomics       Date:  2017-03       Impact factor: 4.981

Review 4.  Asenapine: a review of its use in the management of mania in adults with bipolar I disorder.

Authors:  Claudine M Chwieduk; Lesley J Scott
Journal:  CNS Drugs       Date:  2011-03       Impact factor: 5.749

5.  Adjunctive Behavioral Activation for the Treatment of Bipolar Depression: A Proof of Concept Trial.

Authors:  Lauren M Weinstock; Caitlin Melvin; Mary K Munroe; Ivan W Miller
Journal:  J Psychiatr Pract       Date:  2016-03       Impact factor: 1.325

Review 6.  Mania: diagnosis and treatment recommendations.

Authors:  Gin S Malhi; Michelle Tanious; Michael Berk
Journal:  Curr Psychiatry Rep       Date:  2012-12       Impact factor: 5.285

Review 7.  A decision analysis of long-term lithium treatment and the risk of renal failure.

Authors:  U Werneke; M Ott; E Salander Renberg; D Taylor; B Stegmayr
Journal:  Acta Psychiatr Scand       Date:  2012-03-09       Impact factor: 6.392

8.  Bipolar disorders in Australia. A population-based study of excess costs.

Authors:  Laura J Fisher; Robert D Goldney; Eleonora Dal Grande; Anne W Taylor; Graeme Hawthorne
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2006-11-01       Impact factor: 4.519

9.  Management of bipolar depression.

Authors:  Jae Seung Chang; Kyooseob Ha
Journal:  Indian J Psychol Med       Date:  2011-01

10.  Cost effectiveness of strategies to combat neuropsychiatric conditions in sub-Saharan Africa and South East Asia: mathematical modelling study.

Authors:  Dan Chisholm; Shekhar Saxena
Journal:  BMJ       Date:  2012-03-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.